Эскалация адъювантной эндокринотерапии раннего гормонозависимого HER2-отрицательного рака молочной железы: кому, когда и зачем?

В настоящем обзоре представлена эволюция адъювантной эндокринотерапии раннего гормонозависимого HER2-отрицательного рака молочной железы, описан феномен позднего рецидивирования и дано клиническое обоснование для проведения эскалации лечения, проанализированы ключевые этапы метастатического каскада и дано научное обоснование внедрения ингибиторов CDK4/6 в адъювантные режимы терапии. Представлены основные результаты 2 крупных рандомизированных исследований терапии с включением абемациклиба (MonarchE) и рибоциклиба (NATALEE) у больных с ранними стадиями гормонозависимого HER2-отрицательного рака молочной железы, оценены онкологические результаты эскалации лечения и безопасность терапии.

1. Schiavon G., Smith I. Status of adjuvant endocrine therapy for breast. Breast Cancer Res 2014;16(2):206. Available at: http://breast-cancer-research.com/content/16/2/206. DOI: 10.1186/bcr3636

2. Love R.R., Philips J. Oophorectomy for breast cancer: History revisited. J Natl Cancer Inst 2002;94:1433–4. DOI: 10.1093/jnci/94.19.1433

3. Early Breast Cancer Trialists’ Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681–92. DOI: 10.1056/NEJM198812293192601

4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717. DOI: 10.1016/S0140-6736(05)66544-0

5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011;378(9793):771–84. DOI: 10.1016/S0140-6736(11)60993-8

6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–52. DOI: 10.1016/S0140-6736(15)61074-1

7. Pagani O., Francis P.A., Fleming G.F. et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT. J Clin Oncol 2020;38(12):1293–303. DOI: 10.1200/JCO.18.01967

8. Kim H.A., Lee J.W., Nam S.J. et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase III trial. J Clin Oncol 202038(5):434–43. DOI: 10.1200/JCO.19.00126

9. Baek S., Woo Chul N., Sei-Hyun A. et al. Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial. J Clin Oncol 2023;41(31):4864–71. DOI: 10.1200/JCO.23.00557

10. Тюляндин С.А., Артамонова Е.В., Жигулев А.Н. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2023;13:157–200.

11. Pan H., Gray R., Braybrooke J. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836–46. DOI: 10.1056/NEJMoa1701830

12. Davies C., Pan H., Godwin J. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805–16. DOI: 10.1016/S0140-6736(12)61963-1

13. Rea D.W., Gray R.G., Bowden S.J. et al. Overall and subgroup findings of the aTTom trial: A randomized comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer. Eur J Cancer 2013;49:S298–S449.

14. Clement Z., Kollias J., Bingham J. et al. Extended duration of adjuvant aromatase inhibitor in breast cancer: A meta-analysis of randomized controlled trials. Gland Surg 2018;7(5):449–57. DOI: 10.21037/gs.2018.08.03

15. Gray R., Early Breast Cancer Trialists’ Collaborative Group. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women. Cancer Res 2019;79(4 Suppl):GS3-03.

16. Beckwitt C. Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy. University of Pittsburgh, 2018.

17. Slamon D. Rationale and trial design of NATALEE: A phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 2023;15:1–16. DOI: 10.1177/ 17588359231178125

18. Jacobson A. Ribociclib improves overall survival in HR+/HER2–metastatic breast cancer across common genomic and clinical subtypes. Oncologist 2022;27(Suppl 1):S11, S12. DOI: 10.1093/oncolo/oyac010

19. Takahashi N., Shimizu C., Shimomura A., Toi M. Role of abemaciclib in primary breast cancer: A narrative review of MonarchE. Transl Breast Cancer Res 2022;3:3.

20. Slamon D., Diéras V., Rugo H.S. et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 2024;42(9):994–1000. DOI: 10.1200/JCO.23.00137

21. Yamamoto-Ibusuki M., Arnedos M., André F. Targeted therapies for ER+/HER2– metastatic breast cancer. BMC Med 2015;13:137. DOI: 10.1186/s12916-015-0369-5

22. Herbig U., Ferreira M., Condel L. et al. Cellular senescence in aging primates. Science 2006;311(5765):1257. DOI: 10.1126/science.1122446

23. Torres-Guzmán R., Calsina B., Hermoso A. et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget 2017;8:69493–507. DOI: 10.18632/oncotarget.17778

24. Мамедов М. К 25-летию открытия теломеразы. Репликативное старение клеток: итоги полувекового изучения. Биомедицина 2010;(3):34–8.

25. Kovatcheva M., Liu D., Dickson M. et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 2015;6(10):8226–43. DOI: 10.18632/oncotarget.3364

26. Faget D.V., Ren Q., Stewart S. Unmasking senescence: Contextdependent effects of SASP in cancer. Nat Rev Cancer 2019;19:439–53. DOI: 10.1038/s41568-019-0156-2

27. Petroni G., Formenti S., Chen-Kiang S., Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol 2020;20:669–79. DOI: 10.1038/s41577-020-0300-y

28. Zhang J., Bu X., Wang H. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 2018;553:91–5. DOI: 10.1038/NATURE25015.

29. Laphanuwat P., Jirawatnotai S. Immunomodulatory roles of cell cycle regulators. Front Cell Dev Biol 2019;7. DOI: 10.3389/FCELL.2019.00023

30. Chaikovsky A.C., Sage J. Beyond the cell cycle: Enhancing the immune surveillance of tumors via CDK4/6 inhibition. Mol Cancer Res 2018;16:1454–7. DOI: 10.1158/1541-7786.MCR-18-0201

31. Johnston S., Harbeck N., Hegg R. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (MonarchE). J Clin Oncol 2020;38(34):3987–98. DOI: 10.1200/JCO.20.02514

32. Toi M., Boyle F., Im Y.H. et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in MonarchE cohort 1. Oncologist 2023;28(1):e77–e81. DOI: 10.1093/oncolo/oyac234

33. Stephen R.D., Johnston S. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, highrisk early breast cancer (MonarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(1):77–90. DOI: 10.1016/S1470-2045(22)00694-5

34. Rastogi P., O’Shaughnessy J., Martin M. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: Results from a preplanned MonarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 2024;42(9):987–93. DOI: 10.1200/JCO.23.01994

35. Hortobagyi G. Ribociclib + nonsteroidal aromatase inhibitor as adjuvant treatment in patients with HR+/HER2- early breast cancer: Final invasive disease-free survival analysis from the NATALEE trial. SABCS 2023. Abstract GS03-03.

36. Gnant M., Dueck A.C., Frantal S. et al. Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 2021;40(3):282–93. DOI: 10.1200/JCO.21.02554

37. Loibl S., Marmé F., Martin M. et al. Palbociclib for residual highrisk invasive HR-positive and HER2-negative early breast cancer – The Penelope-B trial. J Clin Oncol 2021;39(14):1518–30. DOI: 10.1200/JCO.20.03639

38. Hortobagyi G., Stemmer S., Burris H. et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022;386(10):942–50. DOI: 10.1056/NEJMoa2114663

39. Slamon D.J., Neven P., Chia S. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival. Ann Oncol 2021;32(8):1015–24. DOI: 10.1016/j.annonc.2021.05.353

40. Hurvitz S., Wheatley-Price P., Tripathy D. et al. Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis. J Clin Oncol 2018;36(15 Suppl). DOI: 10.1200/JCO.2018.36.15_suppl.10

41. El Saghir N.S., Sim Yap Y., Eralp Y. et al. Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial. J Clin Oncol 2023;41(16 Suppl). DOI: 10.1200/JCO.2023.41.16_suppl.106